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Introduction
Centrosomes are the major microtubule-organizing centers of 
animal cells and play an important role in organizing the inter-
phase cytoskeleton and poles of the mitotic spindle (Nigg, 2002). 
A single centrosome is comprised of a pair of centrioles sur-
rounded by an amorphous pericentriolar material, and centro-
some duplication is controlled by centriole replication (Loncarek 
and Khodjakov, 2009). In dividing cells, centrioles duplicate 
once per cell cycle adjacent to preexisting centrioles. Errors in 
this process lead to the production of an abnormal centro-
some number that can promote errors in spindle formation and 
subsequent chromosome missegregation (Ganem et al., 2009; 
Silkworth et al., 2009). Moreover, abnormalities in centrosome 
number are often observed in cancer cells; and thus, accurate 
control of centrosome number is critical for the maintenance of 
genome integrity (Nigg, 2006; Holland and Cleveland, 2009).
Centriole duplication is regulated by the conserved pro-
tein kinase Polo-like kinase 4 (Plk4; also known as SAK). 
Overexpression of Plk4 overrides the mechanism that limits 
centriole duplication, leading to multiple rounds of centriole 
duplication within a single cell cycle (Bettencourt-Dias et al., 
2005; Habedanck et al., 2005; Peel et al., 2007; Basto et al., 
2008). Plk4 is aberrantly expressed in human colorectal and 
liver cancer (Macmillan et al., 2001; Ko et al., 2005). Further-
more, Plk4
+/ mice develop spontaneous liver and lung tumors 
(Ko et al., 2005), whereas overexpression of Plk4 promotes 
centrosome  amplification  and  tumorigenesis  in  flies  (Basto   
et al., 2008; Castellanos et al., 2008). Therefore, Plk4 activ-
ity must be precisely regulated to accurately control centriole 
duplication and prevent transformation.
Plk4 is a low abundance protein with a short cellular half-
life (Fode et al., 1996). Plk4 is ubiquitinated and degraded by 
the 26S proteasome (Fode et al., 1996; Cunha-Ferreira et al., 
2009; Korzeniewski et al., 2009; Rogers et al., 2009), and in-
hibiting proteasome function promotes centriole overduplica-
tion in a Plk4-dependent manner (Duensing et al., 2007). The 
SKP1–CUL1–F Box (SCF) complex is an E3 ubiquitin ligase 
comprised of three core subunits (Skp1, Cullin 1, and Rbx1) and 
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Plk4 (Fig. 1 A) were stably expressed in a human cell line 
(DLD-1) in which accurate chromosome segregation maintains 
a pseudodiploid karyotype (Lengauer et al., 1997). To facili-
tate direct comparison, WT and kinase-dead (KD) Plk4-EYFP 
transgenes were integrated at a predefined genomic locus in the 
host cell line using flippase (Flp) recombination target (FRT)/
Flp–mediated recombination. Plk4-EYFP expression was under 
tight tetracycline regulation, allowing temporal control of Plk4 
kinase-induced centriole biogenesis (Fig. S1, A and C). Previ-
ous work has shown that overexpressed Plk4
KD can increase 
centrosome numbers in cycling populations of cells, whereas 
Plk4
WT promotes centrosome amplification in S phase–arrested 
cells (Habedanck et al., 2005), suggesting dual pathways (one 
kinase dependent and another that is kinase independent) for 
Plk4 stimulation of centrosome duplication. Indeed, 48 h after 
induction of Plk4
WT, 60% of asynchronously growing cells 
showed evidence of centriole amplification, whereas induction 
a variable F box protein that recognizes substrates only when 
they are phosphorylated at specific sites (Frescas and Pagano, 
2008). In Drosophila melanogaster cells, the SCF F box pro-
tein Slimb prevents centrosome amplification by ubiquitinating 
and promoting the degradation of SAK/Plk4 (Cunha-Ferreira 
et al., 2009; Rogers et al., 2009). A direct role of -TrCP (the 
vertebrate homologue of Drosophila Slimb) in promoting the 
destruction of Plk4 has not been demonstrated in vertebrates, 
although mouse cells lacking -TrCP have excess centrosomes 
(Guardavaccaro et al., 2003). In this study, we investigate the 
mechanism that limits Plk4 levels in vertebrates and show that 
Plk4 stability is regulated by its own kinase activity.
Results and discussion
To  determine  how  mammalian  Plk4  levels  are  established, 
EYFP-tagged wild-type (WT) and kinase-inactive (D154A) mouse 
Figure 1.  Plk4 kinase activity destabilizes the protein. (A) Schematic of mouse Plk4, showing the location of the kinase domain, the Polo-box domain 
(PBD), and the cryptic Polo-box domain (Swallow et al., 2005). The locations of the AS and KD mutations are also shown. (B) Immunoblot showing the 
expression level of WT and KD Plk4-EYFP transgenes. (C) Titration showing the relative expression level of Plk4
WT and Plk4
KD. (D) Immunoblot showing the 
expression levels of Plk4
WT, Plk4
AS, and Plk4
KD in the presence of DMSO or 1NM-PP1. (E) Immunofluorescence images acquired 48 h after Plk4-EYFP was 
induced with tetracycline. Cells were grown in DMSO or 1NM-PP1. Insets depict an enlargement of centrioles. Red, SAS-6; green, Plk4-EYFP; blue, DNA. 
Bars, 10 µm. (F) Graph quantifying of the proportion of cells with more than four centrioles 48 h after expression of Plk4-EYFP was induced. Cells were 
grown in the presence of either DMSO or 1NM-PP1. Bars represent the mean of at least three independent experiments with >300 cells per condition. 
Error bars represent the SEM.193 Plk4 kinase activity autoregulates its own stability • Holland et al.
The  26  S  proteasome  inhibitor  MG132  was  added  to 
Plk4
WT-  and  Plk4
KD-expressing  cells  to  determine  whether 
Plk4 kinase activity promotes proteasome-mediated Plk4 de-
struction. Plk4
WT but not Plk4
KD was substantially stabilized 
by MG132 treatment (Fig. 2 A). To determine whether kinase- 
active Plk4 is capable of destabilizing Plk4
KD in trans, we in-
duced expression of Plk4
WT-EYFP or Plk4
KD-EYFP in cells con-
stitutively expressing Plk4
KD-Myc. Expression of Plk4
WT-EYFP, 
but  not  Plk4
KD-EYFP,  reduced  the  stability  of  Plk4
KD-Myc, 
demonstrating that Plk4 can promote self-destruction through 
intermolecular phosphorylation (Fig. 2 B).
Our data support a model in which autophosphorylation 
triggers  Plk4’s  destruction  to  self-limit  kinase  activity.  Plk4 
possesses  a  conserved  SCF
-TrCP  phosphodegron,  and  previ-
ous studies in Drosophila cells have implicated a role of this 
two-phosphosite phosphodegron in regulating Plk4’s stability 
(Cunha-Ferreira et al., 2009; Rogers et al., 2009). Therefore, 
we considered the possibility that autophosphorylation (in cis 
or trans) of the -TrCP phosphodegron was required for Plk4 
to promote its own destruction. To test this hypothesis, we cre-
ated a mutant Plk4 in which both phosphorylation sites in the 
-TrCP  destruction  motif  were  mutated  to  alanine  (Plk4
AA;   
Fig. 2 C). Plk4
AA and Plk4
KD both showed a dramatic reduction 
in -TrCP binding, which is consistent with Plk4 autophosphory-
lation of the -TrCP destruction motif in promoting -TrCP 
binding (Fig. 2 E). However, in contrast to Plk4
KD, Plk4
AA was 
ubiquitinated (albeit at a reduced level compared with Plk4
WT) 
in cells (Fig. 2 F) and was only about twofold more stable than 
Plk4
WT (Fig. 2 D). This demonstrates that phosphorylation of 
the -TrCP destruction motif only plays a minor role in regulat-
ing the stability of Plk4 in these human cells.
The  ubiquitination  and  degradation  of  Plk4
AA  (Fig.  2,   
D  and  F)  suggested  that  phosphorylation  of  additional  sites 
is  required  to  promote  Plk4’s  destruction.  Therefore,  mass 
spectrometry (MS) was used to map additional in vitro auto-
phosphorylation sites on GST-Plk4
WT (Fig. S3 A). A densely 
of Plk4
KD caused centriole amplification in a 2.5-fold smaller 
proportion (23%) of cells (Fig. 1, E and F; and Fig. S1 B).
Surprisingly, the total level of Plk4
KD protein was >10-
fold higher than that of Plk4
WT (Fig. 1, B and C), and the level 
of  Plk4
KD  at  the  centriole  was  >45-fold  higher  than  that  of 
Plk4
WT (Fig. S1, D and E), implicating kinase activity of Plk4 as 
a determinant of its stability. To test this hypothesis, we created 
an ATP analogue-sensitive (AS) mutant of Plk4 (Bishop et al., 
2000). Plk4
AS possesses a point mutation at a conserved gate-
keeper residue (L89G) that enlarges the ATP-binding pocket 
and allows the kinase to be selectively inhibited by the bulky 
ATP analogue 1NM-PP1 (Fig. 1 A). To characterize the Plk4
AS 
allele, we expressed and purified recombinant WT, AS, and KD 
GST-Plk4 and tested the ability of the kinase to phosphorylate 
histone H1 in vitro. GST-Plk4
WT phosphorylated itself (in cis or 
trans) and the substrate histone H1, whereas GST-Plk4
KD lacked 
detectable  activity  (Fig.  S2, A  and  B).  In  comparison  with   
GST-Plk4
WT, GST-Plk4
AS exhibited an 2.5 reduction in phos-
phorylation of itself and an 10-fold reduction in phosphory-
lation of the histone H1 (Fig. S2, A and C), which are reductions 
comparable with that observed with a similar Plk1
AS allele that 
was shown to compensate for the loss of endogenous Plk1 in 
cells (Burkard et al., 2007).
As expected, in vitro 1NM-PP1 inhibited the activity of 
GST-Plk4
AS but not GST-Plk4
WT (Fig. S2 C). Therefore, we 
created stable cell lines expressing Plk4
AS-EYFP and examined 
Plk4’s stability and ability to promote centriole amplification 
in the presence or absence of the 1NM-PP1. In the absence 
of drugs Plk4
AS was expressed at a low level that promoted 
centriole overduplication in 64% of cells, which is similar to 
that observed with Plk4
WT (Fig. 1, D–F). In contrast, addition 
of 1NM-PP1 caused a dramatic increase in the abundance of 
Plk4
AS and reduced centriole overduplication to the level ob-
served with Plk4
KD (Fig. 1, D–F). This suggests that the activity 
of Plk4
AS can be inhibited by 1NM-PP1 in vivo and confirms 
that Plk4 kinase activity regulates its own stability.
Figure  2.  Phosphorylation  of  the  -TrCP–
binding motif has a minor effect on the stability 
of mouse Plk4. (A) Cells were treated with or 
without the proteasome inhibitor MG132 for   
8 h and immunoblotted to determine the ex-
pression level of Plk4
WT and Plk4
KD. (B) Expres-
sion of Plk4
WT-EYFP or Plk4
KD-EYFP was induced 
for  24  h  in  cells  constitutively  expressing 
Plk4
KD-Myc. The expression level of the Myc 
and EYFP-tagged Plk4 transgenes was subse-
quently determined by immunoblotting. (C) The 
Plk4
AA  mutant  possesses  two  mutations  that 
prevent phosphorylation of the -TrCP–binding 
motif  (highlighted  in  green).  (D)  Immunoblot 
shows  a  modest  increase  in  the  stability  of 
Plk4
AA. (E) HEK 293 cells were cotransfected 
with Plk4-EYFP and Myc–-TrCP and treated 
with MG132 for 4 h. Plk4-EYFP was purified 
using GBP-coupled beads or beads alone, and 
protein complexes were analyzed by immuno-
blotting.  (F)  HEK  293  cells  were  cotrans-
fected  with  Plk4-EYFP  and  HA-ubiquitin  and 
treated with MG132 for 4 h. Plk4-EYFP was 
purified  using  GBP-coupled  beads  or  beads 
alone, and protein complexes were analyzed 
by immunoblotting.JCB • VOLUME 188 • NUMBER 2 • 2010   194
His-Plk4
24 was reduced by about a third (36%) compared with 
that of His-Plk4
WT (Fig. 3 C). Together, these data demonstrate that 
Plk4 multiply autophosphorylates a 24-aa region (aa 282–305) 
and that this region is not required for kinase activity in vitro.
We next tested whether aa 282–305 were involved in reg-
ulating Plk4 stability in cells. Importantly, deletion of aa 282–
305 (Plk4
24) dramatically stabilized Plk4 (Fig. 3 D). Plk4
24 
induced centriole overduplication in 75% of cells, and such 
cells contained a mean of 17 centrioles per cell compared 
with about eight centrioles for cells expressing Plk4
WT (Fig. 3, 
E–G). This suggests that Plk4 multiply autophosphorylates a 
24-aa phosphodegron (282–305) that is required to destabilize 
kinase-active Plk4.
To determine how phosphorylation contributes to the in-
stability of kinase-active Plk4, we created several Plk4 mutants 
that were defective in phosphorylation at specific sites within 
aa 282–305 (Fig. 4 A): Plk4
AA contains two mutations in the   
phosphorylated  region  containing  13  phosphorylatable  aa 
within a 24-aa stretch (282–305) was identified (Fig. S3, B and C).   
This region contains the previously identified -TrCP two-
phosphosite  phosphodegron  (Cunha-Ferreira  et  al.,  2009;   
Rogers et al., 2009) and is part of a putative PEST domain 
(aa 272–311) previously proposed to destabilize human Plk4 
(Fig. 3 A; Yamashita et al., 2001). Nine peptides within the 
282–305  region  were  identified  with  multiple  (up  to  four) 
phosphorylations, albeit the exact positions of those sites could 
not  be  identified  with  certainty  because  of  the  close  pack-
ing of phosphorylatable amino acids (Fig. S3, B and C). We 
next tested whether Plk4 could autophosphorylate this 24-aa   
domain in vitro. GST-Plk4
WT readily phosphorylated His-Plk4
KD 
(aa 1–416), but His-Plk4
24 (lacking aa 282–305) accumulated 
42% less phosphorylation (Fig. 3 B). Furthermore, although   
kinase-active  His-Plk4
WT  and  His-Plk4
24  phosphorylated 
histone H1 with similar efficiency, autophosphorylation of 
Figure 3.  Plk4 autophosphorylates a 24-aa   
region  to  promote  its  own  destruction.  
(A) Schematic showing the localization of the   
24-aa region that is required for Plk4 to pro-
mote its own destruction. The alignment of this 
region, which is rich in potential phosphory-
lation sites (S/T residues), is shown. This puta-
tive -TrCP–binding motif is contained within 
this region and marked by a line. (B) GST-Plk4 
kinase assays were performed using His-Plk4
KD 
(aa 1–416) as a substrate. GST-Plk4
WT phos-
phorylates itself and His-Plk4
KD, but note that 
phosphorylation of His-Plk4
KD is reduced by the 
24  mutation.  Coomassie-stained  gel  shows 
the  purified  protein,  and  the  autoradiogram 
shows the incorporation of [
32P]ATP. Assays 
were performed for 60 min, and activity was 
measured by scintillation counting. (C) His-Plk4 
(aa 1–416) kinase assay was performed using 
histone H1 as a substrate. Despite the fact that 
WT and 24 His-Plk4 have similar activity to-
ward histone H1, His-Plk4
24 displays reduced 
autophosphorylation. Coomassie-stained gel 
shows the purified protein, and autoradiogram 
shows the incorporation of [
32P]ATP. Assays 
were performed for 60 min, and activity was 
measured by scintillation counting. (D) Immuno-
blot showing the relative expression levels of 
WT, AA, 24, and KD Plk4-EYFP. (E) Graph 
quantifying of the proportion of cells with more 
than four centrioles 48 h after induction of Plk4-
EYFP. (F) Graph quantifying the mean number 
of centrioles per cell in cells with more than 
four centrioles. Counting was performed 48 h 
after induction of Plk4-EYFP. (G) Immunofluores-
cence images acquired 48 h after Plk4-EYFP 
was induced. Insets depict an enlargement of 
centrioles. Red, SAS-6; green, Plk4-EYFP; blue, 
DNA. Bars, 10 µm. C, Coomassie. Bars rep-
resent the mean of at least three independent 
experiments  with  >280  cells  per  condition.   
Error bars represent the SEM.195 Plk4 kinase activity autoregulates its own stability • Holland et al.
we favor the interpretation that Plk4 directly promotes its own 
destruction  through  autophosphorylation  of  a  13-site  multi-
phosphodegron (Fig. 4 E). The multiphosphodegron possesses 
a conserved -TrCP–binding site previously implicated in regu-
lating the stability of Drosophila Plk4 (Cunha-Ferreira et al., 
2009; Rogers et al., 2009). A mutant of mouse Plk4 unable to be 
phosphorylated in the -TrCP–binding site (Plk4
AA) exhibited 
dramatically  reduced  -TrCP  binding;  however,  Plk4
AA  was 
ubiquitinated and only modestly stabilized in cells. In contrast, 
deletion of the entire 24-aa multiphosphodegron or mutation of 
all 13 phosphorylation sites in this region dramatically stabi-
lized Plk4, suggesting that autophosphorylated Plk4 interacts 
with additional SCF F box proteins or alternative E3 ubiqui-
tin ligases that are required for degradation. Surprisingly, we 
found that repression of -TrCP stabilized Plk4
AA, indicating 
that SCF
-TrCP still contributes to the destruction of this mutant   
(Fig. S3 D). Although we suspect that this arises from an in-
direct effect of -TrCP depletion, it is possible that the small 
amounts of -TrCP associated with Plk4
AA still play a role in 
targeting the protein for destruction.
Because Plk4 phosphorylation occurs in dynamic equilib-
rium with counteracting phosphatases, we speculate that a re-
quirement for multisite phosphorylation to prime degradation is 
-TrCP  phosphodegron,  Plk4
A1  possesses  mutations  in  the 
seven  most-conserved  phosphorylation  sites  downstream  of 
the -TrCP phosphodegron, Plk4
A2 contains mutations in the 
-TrCP phosphodegron and five downstream phosphorylation 
sites, Plk4
A3 has nine phosphorylation sites mutated, and Plk4
A4 
has all 13 phosphorylation sites abolished. Expression of these 
mutants in cells revealed that Plk4 became progressively stabi-
lized as more phosphorylation sites were abolished (Fig. 4 A).   
The  stability  of  the  various  Plk4  phosphorylation  mutants 
closely mirrored their capacity to drive centriole overduplica-
tion in cells, with both the proportion of cells with supernumer-
ary centrioles and the numbers of centrioles per cell increasing 
as  more  phosphorylation  sites  were  mutated  (Fig.  4,  B–D). 
These data imply that autophosphorylation within aa 282–305 
has an additive effect on promoting Plk4’s destruction and acts 
to self-limit Plk4 activity and centriole duplication in cells.
Together, our results show that Plk4’s kinase activity auto-
regulates Plk4 protein stability. Our data do not exclude the pos-
sibility that Plk4 activity regulates stability through additional 
proteins; for example, Plk4-induced activation of an unknown 
kinase may regulate Plk4 stability. However, we demonstrate 
that Plk4 is capable of autophosphorylating a region crucial for 
the kinase activity-dependent degradation of Plk4. Therefore, 
Figure 4.  Phosphorylation of multiple sites is required for optimal Plk4 destruction. (A) Alignment showing the positions of the different phosphorylation 
mutations in Plk4. Immunoblot showing the relative expression levels of WT, AA, A1, A2, A3, A4, and KD Plk4-EYFP. (B) Graph quantifying of the propor-
tion of cells with more than four centrioles 48 h after induction of Plk4-EYFP. Uninduced samples (Tet) are shown for comparison. (C) Graph quantifying 
the mean number of centrioles per cell in cells with more than four centrioles. Counting was performed 48 h after induction of Plk4-EYFP. Uninduced 
samples are shown for comparison. (D) Immunofluorescence images acquired 48 h after Plk4-EYFP was induced. Insets depict an enlargement of centrioles.   
Red, SAS-6; green, Plk4-EYFP; blue, DNA. Bars, 10 µm. (E) A model for the autoregulation of Plk4 stability. Bars represent the mean of at least three inde-
pendent experiments with >300 cells per condition. Error bars represent the SEM.JCB • VOLUME 188 • NUMBER 2 • 2010   196
Staining was performed with antibodies SAS-6 (human anti–SAS-6; pro-
vided by A. Dammermann, Ludwig Institute for Cancer Research, San   
Diego, CA) and GTU-88 (mouse anti–-tubulin; 1:250; Abcam). YFP was 
visualized directly using a GFP filter set, the human SAS6 antibody was 
directly conjugated to Cy5 (Jackson ImmunoResearch Laboratories, Inc.), 
and GTU88 was stained with a secondary goat anti–mouse antibody 
conjugated to AMCA.
Immunofluorescence images were collected using an inverted micro-
scope (IX-70; Olympus) with a Deltavision Core system (Applied Precision) 
controlling an interline charge-coupled device camera (CoolSNAP; Roper 
Industries) driven by softWoRx software (Applied Precision). Images were 
collected using a 100× or 60× 1.4 NA oil objective (Olympus) at 0.2-µM 
z sections and subsequently deconvolved. Imaging was performed at room 
temperature, and maximum intensity 2D projections were assembled for 
each image using softWoRx. With the exception of the images in Fig. S1 E,   
EYFP exposure times were adjusted for each Plk4-EYFP mutant. Centriole 
numbers were determined by counting the number of structures that stained 
positive for both Plk4-EYFP and SAS-6. For quantitation of EYFP, signal in-
tensity at the centriole unconvolved 2D maximum-intensity projections was 
saved as unscaled 16-bit TIFF images. Signal intensity was determined 
using MetaMorph (MDS Analytical Technologies) by drawing a 20 × 20–
pixel box and a larger 25 × 25–pixel box around the centrosome. The 
integrated EYFP intensity in the smaller box was calculated by subtracting 
the mean fluorescence intensity in the area between the two boxes (mean 
background) from the mean GFP intensity in the smaller box and multiply-
ing by the area of the smaller box.
Protein purification
GBP was purified from Escherichia coli (strain Rosetta [DE3]) and covalently 
coupled to NHS-activated Sepharose 4 Fast Flow beads (GE Healthcare) at 
1 mg/ml as described previously (Rothbauer et al., 2008). Recombinant 
His-Plk4 (aa 1–416) was transformed in E. coli (strain Rosetta [DE3]), and 
protein expression was induced at 16°C for 18 h with 200 nM IPTG. 
Bacterial pellets were suspended in lysis buffer (50 mM Tris-HCl, pH 8.0,   
100 mM NaCl, 20 mM imidazole, 0.1% -mercaptoethanol, 0.1% NP-40,   
1 mM PMSF, and 1 µM LPC) and lysed by sonication after 1 mg/ml lyso-
zyme treatment on ice for 30 min. After centrifugation at 15,000 rpm   
(SA-600; Sorvall) for 30 min, the supernatant was incubated with pre-
washed nickel nitrilotriacetic acid beads (QIAGEN) for 1 h at 4°C. 
Beads were washed extensively in wash buffer (50 mM Tris-HCl, pH 8.0, 
500  mM  NaCl,  20  mM  imidazole,  0.1%  -mercaptoethanol,  0.1%   
NP-40, 1 mM PMSF, and 1 µM LPC), and protein was eluted in elution buffer   
(50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 300 mM Imidazole, 0.1%   
-mercaptoethanol, and 0.1% NP-40). Proteins were dialyzed into a final 
buffer containing 50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 20 mM imidaz-
ole, and 0.1% -mercaptoethanol. Recombinant GST-Plk4 was expressed 
and purified from insect cells (High Five; Invitrogen) using the Bac-to-Bac 
expression system (Invitrogen). Infected cell pellets were suspended in lysis 
buffer (PBS supplemented with 2 mM MgCl2, 5 mM DTT, 10 nM micro-
cystin, 1 mM Na3V04, 250 U benzonase nuclease [Sigma-Aldrich], 1 mM 
PMSF, and 1 mM LPC) and lysed by sonication. After centrifugation at 
15,000 rpm (SA-600; Sorvall) for 30 min, the supernatant was supple-
mented with 110 mM KCL and 0.1% Triton X-100 and incubated with gluta-
thione Sepharose (GE Healthcare) for 1 h at 4°C. Beads were washed 
extensively in wash buffer (PBS supplemented with 1 mM DTT, 0.1% Triton 
X-100, 100 mM KCL, 1 mM PMSF, and 1 µM LPC), and protein was eluted 
in elution buffer (1× PBS supplemented with 40 mM reduced glutathione, 
50 mM Tris, pH 8.0, and 5 mM DTT).
In vitro kinase assays
In vitro kinase assays were performed at room temperature in 20 mM Tris, 
pH 7.5, 25 mM KCl, 10 mM MgCl2, 1 mM DTT, 5 µM Na3V04 in the pres-
ence of 50 µM ATP, and 100 µCi/ml [
32P]ATP. 2 µg of substrate was incu-
bated with 1 µg purified GST-Plk4 or 2 µg His-Plk4 (aa 1–416). Kinase 
reactions were stopped with sample buffer and analyzed by SDS-PAGE. 
For quantification, individual bands were excised, and the incorporation of 
32P  was  quantified  using  a  scintillation  counter  (Beckman  Coulter).  For   
 phosphatase treatment, GST-Plk4 was incubated with  phosphatase 
(New England Biolabs, Inc.) at 30°C for 30 min.
MS sample preparation
20 µg trichloroacetic acid–precipitated GST-Plk4
WT was dissolved in 8 M 
urea and 100 mM Tris, pH 8.0, with a final volume of 25 µl. The protein 
was reduced in 5 mM TCEP (Fluka) for 20 min at room temperature and   
alkylated in 10 mM iodoacetamide (Sigma-Aldrich) for 15 min in the dark. 
Each sample was diluted fourfold with 100 mM Tris, pH 8.0, and CaCl2 
likely to provide a temporal delay to allow Plk4 to phosphory-
late critical substrates required for centriole duplication before 
its protein level is down-regulated. This could create a sensitive 
biological switch in which Plk4 can be rapidly destabilized once its 
activity reaches a certain threshold level. This autoregulatory 
feedback loop places Plk4 stability under direct control of its 
own activity and may form an important mechanism to limit 
normal centriole duplication to once per cell cycle.
Materials and methods
Constructs
The full-length mouse Plk4 open reading frame was cloned into a pcDNA5/
FRT/TO-based vector (Invitrogen) modified to contain a C terminus EYFP 
or Myc epitope tag. To create Plk4
A1 and Plk4
A4, two silent point mutations 
were introduced to create an NheI site at aa 225–226. A fragment of 
mouse Plk4 (aa 223–387) encoding the appropriate mutations was syn-
thesized (Genscript) and used to replace a corresponding NheI–XhoI frag-
ment in mouse Plk4. All other Plk4 mutants were generated by site-directed 
mutagenesis  (QuickChange;  Agilent  Technologies).  To  create  His-Plk4   
(aa 1–416), the first 416 aa of mouse Plk4 were amplified by PCR and 
cloned into a pET30 bacterial expression vector (EMD), which contains 
an N-terminal 6His tag. To create GST-Plk4, the mouse Plk4 open read-
ing frame was cloned into a pFastBac1 (Invitrogen)-based vector modified 
to contain an N terminus GST tag. pcDNA3 Myc–-TrCP and pcDNA3   
HA-ubiquitin plasmids were obtained from Addgene.
Cell culture
Cells were maintained at 37°C in a 5% CO2 atmosphere in DME contain-
ing  10%  tetracycline-free  FBS  (Takara  Bio  Inc.),  100  U/ml  penicillin,   
100 U/ml streptomycin, and 2 mM L-glutamine. DLD-1 cells were used in 
all experiments except in Fig. 2 (E and F), which used HEK 293 cells.
Generation of stable cell lines and siRNA treatment
RFP-tagged histone H2B (H2B-RFP) was introduced into Flp-In TRex-DLD-1 
parental cells (provided by S. Taylor, The University of Manchester, Man-
chester, England, UK) using retroviral delivery as described previously 
(Shah et al., 2004). Stable integrates were selected in 2 μg/ml puromy-
cin, and single clones were isolated using FACS (FACSVantage; BD). Sta-
ble, isogenic cell lines expressing Plk4-EYFP were generated using the 
FRT/Flp-mediated  recombination  as  described  previously  (Tighe  et  al., 
2004). Expression of Plk4-EYFP was induced with 1 µg/ml tetracycline 
(Sigma-Aldrich). Flp-In TRex-DLD-1 H2B-RFP cells were used for all the ex-
periments except in Fig. 2 (E and F). Small molecules were used at the fol-
lowing final concentrations: nocodazole MG132 (EMD), 20 µM; 1NM-PP1 
(EMD), 10 µM. For siRNA treatment, 1.5 × 10
5 cells were plated in a   
6-well plate, and duplexed siRNAs were introduced using Oligofectamine 
(Invitrogen).  siRNAs  directed  against  -TrCP  (5-GUGGAAUUUGUG-
GAACAUC-3) and GAPDH (5-UGGUUUACAUGAUCCAAUA-3) were 
purchased from Thermo Fisher Scientific. 24 h after transfection, tetra-
cycline was added to induce expression of Plk4-EYFP and cells harvested 
and processed for immunoblotting 24 h later.
Immunoblotting and immunofluorescence
To purify Plk4-YFP, cells were lysed in lysis buffer (10 mM Tris, pH 7.5, 
0.1% Triton X-100, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 50 mM 
NaF, 20 mM -glycerophosphate, 0.1 mM DTT, 200 nM microcystin,   
1 mM PMSF, and 1 µM leupeptin, pepstatin, and chymostatin [LPC]), soni-
cated, and soluble extracts were prepared. The supernatant was incu-
bated with beads alone or beads coupled to GFP-binding protein (GBP; 
Rothbauer et al., 2008). Beads were washed five times in lysis buffer, and 
protein complexes were analyzed by immunoblotting. For immunoblot 
analysis, protein samples were separated by SDS-PAGE, transferred onto 
nitrocellulose membranes (Bio-Rad Laboratories), and probed with anti-
bodies 4A6 (mouse anti-Myc; 1:1,000; Millipore), DM1A (mouse anti– 
-tubulin;  1:1,000),  and  YFP  (mouse  anti-GFP;  1:500;  Roche).  For 
immunofluorescence,  cells  were  grown  on  hydrochloric  acid–washed, 
poly-L-lysine (Sigma-Aldrich)–coated 18-mm glass coverslips and fixed in 
100% ice-cold methanol for 10 min. Cells were blocked in 2.5% FBS, 
200 mM glycine, and 0.1% Triton X-100 in PBS for 1 h. Antibody incuba-
tions were conducted in the blocking solution for 1 h. DNA was detected 
using DAPI, and cells were mounted in Prolong Antifade (Invitrogen). 197 Plk4 kinase activity autoregulates its own stability • Holland et al.
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was added to a final concentration of 1 mM. 0.8 µl trypsin (0.5 µg/µl; 
Promega) was added for an overnight digestion at 37°C. Samples were 
acidified with formic acid to a final concentration of 5% for MS analysis.
MS analysis
The tryptic digest was pressure loaded onto an equilibrated fused silica cap-
illary column containing 3 cm Aqua 5u C18 (Phenomenex) packed into a 
250-µm-i.d. capillary with a filtered union (UpChurch Scientific). Next, an 
equilibrated 100-µm-i.d capillary with a 5-µm pulled tip containing 10 cm of 
C18 material was attached to the filter union and placed in line with a qua-
ternary HPLC (1200; Agilent Technologies). Peptides were separated with a 
2-h organic gradient (Dix et al., 2008) and analyzed on an LTQ-Orbitrap as 
previously described (Lu et al., 2008), except one full Fourier transform scan 
mass spectrum (400–1,800 m/z; resolution of 60,000) was followed by 
nine data-dependent MS/MS acquired in the linear ion trap.
Analysis of MS data
The ms
2 spectra data were extracted from the raw files using the publicly 
available RAW Xtractor (version 1.9.1). Ms
2 spectra data were searched 
using the ProLuCID search algorithm (Xu, T., J.D. Venable, S. Kyu Park,   
D. Cociorva, B. Lu, L. Liao, J. Wohlschlegel, J. Hewel, and J.R. Yates III. 
2006. Human Proteome Organisation Fifth Annual World Congress.   
Abstr. S271) against a custom-made database containing the longest entry 
form of the mouse International Protein Index database (version 3.26) as-
sociated with each Ensembl gene identifier, resulting in a total of 22,833 
unique entries. Additionally, each of these entries was reversed and ap-
pended to the database for assessment of false-positive rates. In total, 
the search database contained 45,666 protein sequence entries (22,833 
real sequences and 22,833 decoy sequences). Searches allowed for the 
static modification of cysteine residues (57.02146 D; because of alkyla-
tion) and differential modification (79.9663 D; phosphorylation) on serine 
and threonine residues up to a maximum of four residues per peptide. 
In addition, full tryptic enzyme specificity was defined for searches with 
a mass tolerance set to 100 ppms for precursor mass and 600 ppm for 
product ion masses. The resulting ms
2 spectra matches were assembled 
and filtered using DTASelect2 (version 2.0.27). For this analysis, modi-
fied  and  unmodified  peptides  were  each  individually  evaluated  using 
the DTASelect2 software. In each of these subgroups, the distribution of   
Xcorr and DeltaCN values for a direct (to the direct database) and decoy 
(reversed database) were separated by quadratic discriminant analysis.   
Spectral matches were retained with Xcorr and deltaCN values that pro-
duced a maximum peptide false-positive rate of 1% that was derived from 
the frequency of matches to the decoy reverse database (number of decoy 
database hits/number of filtered peptides identified × 100). This value 
is calculated by the DTASelect2 software. In addition, a minimum pep-
tide length of 6-aa residues was imposed. Such criteria resulted in the 
elimination of most decoy database hits. Modified peptides were further 
validated using Debunker (Lu et al., 2007).
Online supplemental material
Fig.  S1  shows  that  kinase  activity  destabilizes  centriole-localized  Plk4.   
Fig. S2 shows that an AS mutant of recombinant Plk4 can be inhibited with 
the ATP analogue 1NM-PP1. Fig. S3 shows in vitro phosphorylation analy-
sis of recombinant GST-Plk4. Online supplemental material is available at 
http://www.jcb.org/cgi/content/full/jcb.200911102/DC1.
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